See the DrugPatentWatch profile for tasigna
How do Tasigna and Gleevec compare for CML treatment?
Tasigna (nilotinib) and Gleevec (imatinib) are both tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia (CML). Gleevec was the first approved in 2001 and set the standard, achieving major cytogenetic response (MCyR) rates around 85% at 5 years in trials.[1] Tasigna, approved later in 2007, shows higher and faster response rates—MCyR of 96% at 2 years and deeper molecular responses (MMR) in 66% vs. 40% for Gleevec in the ENESTnd trial.[2] Tasigna reaches MMR faster (12 months vs. 19 months).[1]
Why do guidelines prefer Tasigna over Gleevec now?
NCCN and ELN guidelines recommend Tasigna or dasatinib over Gleevec for newly diagnosed chronic-phase CML due to superior efficacy in achieving deeper, quicker responses, which correlate with better long-term outcomes like progression-free survival.[3] In head-to-head trials like ENESTnd (5-year follow-up), Tasigna had lower rates of progression to accelerated/blast phase (0.9% vs. 1.6% for Gleevec).[2] Gleevec remains effective but is less potent against certain BCR-ABL mutations.
What about side effects and safety differences?
Tasigna carries higher risks of QT prolongation, hyperglycemia, and pancreatitis, requiring ECG monitoring and glucose checks.[1] Gleevec more often causes fluid retention, nausea, muscle cramps, and rash, with easier tolerability for many patients.[4] Discontinuation rates are similar (around 7-10% in trials), but Tasigna links to more cardiovascular events in some studies.[2] Patient choice often weighs these against efficacy gains.
Can you switch from Gleevec to Tasigna?
Yes, switching is common if suboptimal response on Gleevec (e.g., no MCyR by 12 months) or intolerance. Tasigna achieves MMR in 50-60% of switchers per DASISION and ENESTnd extensions.[3] Treatment-free remission trials (e.g., ENESTfreedom) show Tasigna patients more often qualify for stopping therapy after sustained deep response.
Cost and access considerations
Gleevec costs about $10,000/month without insurance (generics available since 2016 at ~$100/month).[5] Tasigna generics launched in 2023, dropping prices to $200-500/month, making it comparable.[5] Patent data confirms Tasigna's key composition patent expired March 2023, enabling generics.[6]
When is Gleevec still a good choice?
Gleevec suits patients with heart risks (avoids QT issues) or those prioritizing milder GI side effects. It's viable first-line if cost is a barrier pre-generic Tasigna, with real-world data showing 10-year survival over 80%.[1]
[1]: FDA Labels - Gleevec
[2]: NEJM - ENESTnd Trial
[3]: NCCN CML Guidelines v2.2024
[4]: Lancet Oncology - Safety Comparison
[5]: GoodRx Pricing Data
[6]: DrugPatentWatch - Tasigna Patents